Sulfuric Acid

Sulfuric Acid

SCHEMBL21815641

O=S(=O)([O-])O.O=S(=O)([O-])O.O=S(=O)([O-])O.[La+3]

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CYP51cyp51Acyp51c

The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.80
MEN1 O00255 1/20 0.80
ALDH1A1 P00352 1/20 0.80
KMT2A Q03164 1/20 0.80
CA5A P35218 2/20 0.50
CA5B Q9Y2D0 2/20 0.50
CA2 P00918 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
CA1 P00915 1/20 0.42
NT5E P21589 1/20 0.42
CA4 P22748 1/20 0.42
CA6 P23280 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
TP53 P04637 1/20 0.35
BLM P54132 1/20 0.31
KDM4E B2RXH2 1/20 0.31
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL28291978 0.95 TSHR (0.73) TSHRMEN1ALDH1A1KMT2ACA5A
Sulfuric Acid SCHEMBL7645188 0.89 TSHR (0.80) TSHRMEN1ALDH1A1KMT2ACA5A
Sulfuric Acid SCHEMBL8192555 0.89 TSHR (0.80) TSHRMEN1ALDH1A1KMT2ACA5A
Sulfuric Acid SCHEMBL2813622 0.89 TSHR (0.80) TSHRMEN1ALDH1A1KMT2ACA5A
Sulfuric Acid SCHEMBL6380732 0.89 TSHR (0.80) TSHRMEN1ALDH1A1KMT2ACA5A
Sulfuric Acid SCHEMBL27312 0.89
Sulfuric Acid SCHEMBL2814083 0.89
Sulfuric Acid SCHEMBL21815678 0.89 TSHR (0.80) TSHRMEN1ALDH1A1KMT2ACA5A
Sulfuric Acid SCHEMBL4306353 0.89 TSHR (0.80) TSHRMEN1ALDH1A1KMT2ACA5A
Sulfuric Acid SCHEMBL8192552 0.89 TSHR (0.80) TSHRMEN1ALDH1A1KMT2ACA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114069028-B Preparation method of composite solid electrolyte membrane and all-solid lithium battery 明志科技大学 2024-05-03 CN claimed
US-11799170-B2 Method for fabricating gallium-doped lithium lanthanum zirconate, and all-solid-state battery including the same MING CHI UNIVERSITY OF TECHNOLOGY (TW) 2023-10-24 US claimed
CN-116315046-A Method for improving brittleness of LLZO/PEO composite electrolyte membrane and application 西安交通大学 2023-06-23 CN claimed
CN-114069028-A Preparation method of composite solid electrolyte membrane and all-solid-state lithium battery 明志科技大学 2022-02-18 CN claimed
US-20220045402-A1 METHOD FOR THE FABRICATION OF A HYBRID SOLID ELECTROLYTE MEMBRANE, AND AN ALL-SOLID-STATE LITHIUM BATTERY USES THE MEMBRANE MING CHI UNIVERSITY OF TECHNOLOGY (TW) 2022-02-10 US claimed
CN-112195038-A Crude oil treating agent and preparation method thereof 四川润和催化新材料股份有限公司 2021-01-08 CN claimed
US-12594345-B2 Degradable hyaluronic acid hydrogels ASCENDIS PHARMA A/S (DK) 2026-04-07 US disclosed
CN-114069028-B Preparation method of composite solid electrolyte membrane and all-solid lithium battery 明志科技大学 2024-05-03 CN disclosed
US-11799170-B2 Method for fabricating gallium-doped lithium lanthanum zirconate, and all-solid-state battery including the same MING CHI UNIVERSITY OF TECHNOLOGY (TW) 2023-10-24 US disclosed
CN-116315046-A Method for improving brittleness of LLZO/PEO composite electrolyte membrane and application 西安交通大学 2023-06-23 CN disclosed
CN-114069028-A Preparation method of composite solid electrolyte membrane and all-solid-state lithium battery 明志科技大学 2022-02-18 CN disclosed
US-20220045402-A1 METHOD FOR THE FABRICATION OF A HYBRID SOLID ELECTROLYTE MEMBRANE, AND AN ALL-SOLID-STATE LITHIUM BATTERY USES THE MEMBRANE MING CHI UNIVERSITY OF TECHNOLOGY (TW) 2022-02-10 US disclosed
US-20210338834-A1 DEGRADABLE HYALURONIC ACID HYDROGELS ASCENDIS PHARMA A/S (DK) 2021-11-04 US disclosed
US-20210330798-A1 TREATMENT OF INFECTIONS ASCENDIS PHARMA A/S (DK) 2021-10-28 US disclosed
EP-3856257-A1 DEGRADABLE HYALURONIC ACID HYDROGELS Ascendis Pharma A/S (DK) 2021-08-04 EP disclosed
EP-3856255-A1 TREATMENT OF INFECTIONS Ascendis Pharma A/S (DK) 2021-08-04 EP disclosed
CN-113164616-A Degradable hyaluronic acid hydrogel 阿森迪斯药物股份有限公司 2021-07-23 CN disclosed
CN-112195038-A Crude oil treating agent and preparation method thereof 四川润和催化新材料股份有限公司 2021-01-08 CN disclosed
WO-2020064844-A1 TREATMENT OF INFECTIONS ASCENDIS PHARMA A/S (DK) 2020-04-02 WO disclosed
WO-2020064847-A1 DEGRADABLE HYALURONIC ACID HYDROGELS ASCENDIS PHARMA A/S (DK) 2020-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210338834-A1 DEGRADABLE HYALURONIC ACID HYDROGELS CD44, HPSE, MMP13 TSHR 1264/4885MEN1 2545/4885ALDH1A1 101/4885
US-12594345-B2 Degradable hyaluronic acid hydrogels CD44, H1-0, MMP1 TSHR 493/4885MEN1 2382/4885ALDH1A1 210/4885
US-20210330798-A1 TREATMENT OF INFECTIONS H1-10, PM20D2, ELANE TSHR 3454/4885MEN1 1654/4885ALDH1A1 1667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.